Board summary
Key figures
101,996
Registered population
59.9% aged 18–64
20.5%
Aged 65+
ICB 15.7% · England 17.9%
14.2%
Ethnic minority (non-White)
8.5% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 3.0% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
15,545
Hypertension register
+2.66% in 3 yrs · England +5.60%
662
SMI register
92.6% of Surrey Heath's
1,363
COPD register
Reviews +39.83% in 3 yrs
Forecast to 2030
17,073
Hypertension patients, 2030
+1,528 on today
70.0%
QRISK ≥20% on statins, 2030
+4.97pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review rate trails England and ICB.
Annual asthma reviews reached 62.7% (England 65.7%, ICB 68.4%), leaving about 2,200 of 6,012 register patients unreviewed, which may reflect recall gaps.
High-risk lipid therapy lags alongside higher costs.
Lipid therapy in QRISK ≥ 20% is 58.6% (England 63.6%, ICB 64.7%), while lipid-modifying prescribing costs £98,151 more than at England's unit cost.
COPD and heart failure reviews rose sharply.
From 2023 to 2025, COPD reviews rose +39.8% to 80.2% (England 76.4%) and heart failure reviews rose +15.5% to 83.1% (England 78.5%).
Population, age and ethnicity
An older population with 20.5% aged 65+ shapes primary care and frailty demand
Surrey Heath PCN comprises 101,996 registered patients. Older adults aged 65+ account for 20.5% (20,933 patients), exceeding Surrey Heath (19.3%), NHS Frimley ICB (15.7%) and England (17.9%). Unverified projections indicate 3.3% list growth to 2030 (Surrey Heath 2.8%, ICB 2.5%, England 2.3%). Based on area Census residents rather than GP registers, White groups comprise 85.8% (Surrey Heath 85.0%, ICB 74.1%, England 81.1%), Asian groups 8.5% (Surrey Heath 8.9%, ICB 17.3%, England 9.6%), and Gypsy or Irish Traveller residents 0.4% (Surrey Heath 0.2%, ICB 0.2%, England 0.1%).
Age profile
65+: ICB 15.7%, England 17.9%
Ethnicity
Older people · falls rows are Surrey Heath local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Surrey Heath LA) | 1,638 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.5% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.0% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Surrey Heath LA) | 726 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Surrey Heath LA) | 12.1 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 0.0% across all practices, with an average IMD decile of 8.4
Core20 deprivation is 0.0%, matching Surrey Heath (0.0%), below NHS Frimley ICB (3.0%) and England (21.0%). Average IMD decile is 8.4 against Surrey Heath's 8.6, the ICB's 7.5 and England's 5.5 decile, with 0 Core20 residents across 72 LSOAs. All seven practices record 0.0% Core20 share. The PCN accounts for 92.6% of the borough severe mental illness register (662 patients) and 93.7% of the learning disability register (472 patients). Blood pressure checks for severe mental illness trail NHS Frimley ICB (79.9% versus 87.0%), highlighting an outreach focus.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
662
SMI register
0.64% recorded prevalence
472
Learning disability register
0.46% recorded prevalence
42
Care homes, 1,978 beds
In the PCN catchment
7.5%
Provide unpaid care
Surrey Heath, Census 2021
The PCN records 472 learning disability patients (0.5% prevalence) and 662 severe mental illness patients, representing 93.7% and 92.6% of borough registers respectively, alongside 42 catchment care homes with 1,978 beds. Unlinked borough data includes an autumn snapshot of 10 rough sleepers in 2025 and an estimated ceiling of 7,650 unpaid carers.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reached 79.9% (Surrey Heath 80.5%, England 83.4%, NHS Frimley ICB 87.0%) and BMI checks reached 79.5% (Surrey Heath 79.1%, England 82.1%, ICB 87.2%). Trailing ICB completion could reflect recall gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
15,545
Hypertension register
+2.66%
Register growth, 3 yrs
Surrey Heath +3.31% · England +5.60%
+6.16pp
BP control, under 80
≤140/90 · +4.68pp aged 80+
+1,528
More patients by 2030
Forecast 17,073 (15.81%)
Hypertension case-finding and control
Hypertension register prevalence is 15.0% (15,545 patients), compared with 14.8% in Surrey Heath, 14.4% in NHS Frimley ICB and 15.2% in England. Over 2023 to 2025, register growth was +2.7% (Surrey Heath +3.3%, ICB +4.1%, England +5.6%). Recorded blood pressure checks stand at 87.5% (Surrey Heath 87.4%, ICB 90.1%, England 90.0%). Blood pressure control under age 80 is 66.5% (Surrey Heath 66.3%, ICB 69.6%, England 67.8%), and treatment to target is 69.3% (Surrey Heath 69.4%, ICB 71.6%, England 70.3%). Proactive recall for unmanaged hypertensive patients could help narrow gaps to ICB and national control benchmarks.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy reached 58.6% (Surrey Heath 59.0%, England 63.6%, NHS Frimley ICB 64.7%), following +9.3% change over 2023 to 2025 (Surrey Heath +8.6%, ICB +5.0%, England +6.2%). Prioritising recall of eligible high-risk patients may address treatment shortfalls.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 153,361 | £2.50 | £2.23 | £1.86 | £383,402 |
| Cardiovascular (all), 2025 | 215,706 | £4.18 | £4.03 | £3.33 | £901,651 |
In 2026, the PCN prescribed 153,361 lipid-regulating drug items at £2.50 per item (Surrey Heath £2.49, NHS Frimley ICB £2.23, England £1.86). The PCN spent £98,151 more than at England's unit cost across 153,361 items. Prescribing choices across member practices drive higher spend than ICB and national benchmarks.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+8.79%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.18%
Asthma prevalence, PCN 3-yr % change
COPD reviews reached 80.2% after a +39.8% three-year increase over 2023 to 2025, exceeding Surrey Heath (79.9%), NHS Frimley ICB (79.4%) and England (76.4%). Conversely, asthma reviews reached 62.7% (Surrey Heath 62.5%, England 65.7%, ICB 68.4%), leaving about 2,200 of 6,012 registered patients without a recorded review. Asthma smoking status recording at ages 6-19 was 72.1% (Surrey Heath 72.6%, England 78.8%, ICB 81.3%). Proactive recall could close gaps in adult and paediatric asthma reviews.
Cancer register and children's immunisation
Cancer prevalence is 4.0% (4,126 patients; Surrey Heath 4.1%, NHS Frimley ICB 3.6%, England 3.8%). In Q1 2025/26 at age five, MMR dose 1 reached 95.7% (ICB 93.3%, England 91.7%). However, MMR dose 2 reached 88.8% (ICB 88.0%, England 82.8%), showing a 6.9 pp difference, and the 4-in-1 booster reached 88.4% (ICB 87.4%, England 80.9%), both below the 95.0% target. Recall drop-off after age one may explain slower pre-school booster completion.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
57.3%
Frimley ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~500
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Frimley ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.3% | 85.4% | 21% | 537 |
| Prostate | 52.0% | 53.2% | 22% | 440 |
| Bowel | 50.2% | 47.0% | 17% | 406 |
| Lung | 33.3% | 33.8% | 16% | 324 |
| Skin cancer | 84.4% | 87.8% | 17% | 225 |
In 2022, 57.3% of cancers with a known stage in NHS Frimley ICB were diagnosed at stage 1 or 2 (1,622 of 2,830 staged cases; England 55.3%), with a distance of -17.7 pp to the 75.0% national ambition by 2028, representing about 500 extra early-stage cases a year. Known-stage share was 67.8% (2,830 of 4,174 cases). Bowel cancer early diagnosis was 50.2% (204 of 406 staged cases). At PCN level, cervical screening coverage is 69.9% (England 66.8%), falling -1.9% over three years. Screening uptake and prompt referral in primary care are key to improving early staging across the system.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Jul 2026 (provisional) figures describe trust and ICB waiting times rather than PCN delivery. Frimley Health NHS Foundation Trust achieved 81.8% on the 62-day referral to treatment standard (85.0% standard; -3.2 pp distance), ahead of England (71.2%) and NHS Surrey and Sussex Integrated Care Board (71.5%), but below Royal Surrey NHS Foundation Trust (84.5%). On the 28-day faster diagnosis standard (75.0% standard), Frimley Health achieved 87.9% (12.9 pp distance), exceeding Ashford and St Peter's Hospitals NHS Foundation Trust (85.5%), Royal Surrey NHS Foundation Trust (82.6%) and England (79.3%).
| Pathways within standard (%) | Frimley Health | Royal Surrey | Ashford and St Peter's | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 87.95 | 82.62 | 85.53 | 79.29 | 79.32 |
| 31-day treatment (96%) | 92.89 | 96.43 | 94.21 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 81.84 | 84.48 | 76.38 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Frimley Health | Royal Surrey | Ashford and St Peter's | England |
|---|---|---|---|---|
| MRI | 12.85 | 0.00 | 0.09 | 21.40 |
| CT | 0.63 | 0.15 | 9.27 | 9.92 |
| Echocardiography | 3.35 | 1.55 | 0.97 | 28.48 |
| Colonoscopy | 22.84 | 0.00 | 49.61 | 30.83 |
| Gastroscopy | 7.43 | 0.00 | 56.74 | 29.02 |
| All 15 DM01 tests | 7.49 | 8.82 | 23.12 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In Jun 2026 (provisional), community services recorded 109,530 contacts for Surrey Heath borough residents, of which 76,215 involved adults aged 65 and over (69.6%). These figures describe borough resident activity across the wider health economy rather than PCN-level delivery.
Practice variation and patient experience
Phone access spans 48.9 pp and vaccination achievement varies by 58.2 pp across practices
Overall 2025/26 QOF achievement ranges from 92.4% at Upper Gordon Road Surgery to 98.1% at Station Road Surgery (England 92.5%). Vaccination and immunisation achievement reveals wider variation, spanning 58.2 pp from 39.2% at Upper Gordon Road Surgery to 97.4% at Station Road Surgery (England 55.2%). High overall scores may mask substantial domain-specific variation.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Lightwater Surgery | 108 | 0.0 | 86.6% | 75.0% | 95.2% |
| Station Road | 125 | 0.0 | 81.0% | 73.3% | 90.5% |
| Park House Surgery | 105 | 0.0 | 49.2% | 77.1% | 83.0% |
| Camberley | 102 | 0.0 | 60.9% | 51.8% | 81.0% |
| Park Road | 106 | 0.0 | 56.0% | 67.6% | 78.7% |
| Bartlett | 97 | 0.0 | 37.6% | 81.4% | 77.0% |
| Upper Gordon Road | 96 | 0.0 | 40.9% | 68.6% | 65.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia and stroke registers contracted over three years while chronic condition reviews improved
Over 2023 to 2025, dementia register change was -5.2% (England +6.0%), while stroke prevalence changed by -2.5% (England +2.3%). In contrast, chronic disease management expanded: COPD reviews rose +39.8% (England +2.8%), and heart failure reviews rose +15.5% (England +8.7%) to 83.1% (England 78.5%). Blood pressure control under age 80 rose +10.2% (England +3.2%). Improving clinical reviews alongside contracting registers may reflect coding cleanup, turnover, or unverified detection gaps, which practice audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Stroke register
Breast screening (53-70)
Hypertension register
Asthma register
COPD reviews
BP control, under 80
Heart failure reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Surrey Heath | Asset | PCN | Surrey Heath |
|---|---|---|---|---|---|
| Care homes (catchment) | 42 (1,978 beds) | n/a | Schools (catchment) | 99 | n/a |
| Children's centres | 8 | 6 | Places of worship | 52 | 37 |
| Libraries | 4 | 3 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 9 | 5 | Primary academies | 26 | 22 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review completion is 62.7% (Surrey Heath 62.5%, England 65.7%, NHS Frimley ICB 68.4%), leaving 2,244 (about 2,200) of 6,012 registered patients without a recorded review. For discussion: practices could run a shared recall template with flexible slots, reviewing inhaler prescribing alongside annual asthma checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Stroke and dementia register audit
Stroke prevalence is 1.7% (1,785 patients; Surrey Heath 1.7%, England 1.9%; range -18 to +141 patients) with -2.5% 3-year change (England +2.3%); dementia changed by -5.2% (England +6.0%). For discussion: practices could search clinical records and care home lists for patients with stroke or dementia history lacking a register code. Low cost, quick to run.
Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.
Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.
Option 3
High-risk lipid therapy and formulary review
Lipid-lowering therapy in QRISK ≥ 20% is 58.6% (England 63.6%, ICB 64.7%) and statin therapy in diabetes is 71.3% (ICB 75.1%), while lipid-modifying prescribing costs £98,151 more than at England's unit cost across 153,361 items. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Traveller community outreach review (p2) | Gypsy or Irish Traveller | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Severe mental illness check outreach (p3) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| SMI physical health recall clinics (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertensive blood pressure recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Stroke and dementia register audit (p12) | Stroke register · Stroke: QOF prevalence · Dementia: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT · SSNAP · 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
| Option 3 · High-risk lipid therapy and formulary review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) · Cost per item for Lipid-regulating drugs 2026 | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
